SCHEMBL6204263

SCHEMBL6204263

CCCCNC(=O)CCS

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP2 P42575 1/20 0.61
NAAA Q02083 1/20 0.57
DNM1 Q05193 2/20 0.55
FAAH O00519 4/20 0.53
CNR1 P21554 1/20 0.51
EPHX1 P07099 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
HPGD P15428 2/20 0.46
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46
HDAC5 Q9UQL6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11912070 0.94 CASP2 (0.70) CASP2NAAADNM1FAAHCNR1
SCHEMBL12254784 0.92 CASP2 (0.74) CASP2NAAADNM1FAAHEPHX1
SCHEMBL29290542 0.92 CASP2 (0.74) CASP2NAAADNM1FAAHEPHX1
SCHEMBL21548098 0.92 CASP2 (0.74) CASP2NAAADNM1FAAHEPHX1
SCHEMBL965531 0.92 CASP2 (0.74) CASP2NAAADNM1FAAHEPHX1
SCHEMBL9230007 0.92 CASP2 (0.74) CASP2NAAADNM1FAAHEPHX1
SCHEMBL11132585 0.92 CASP2 (0.74) CASP2NAAADNM1FAAHEPHX1
SCHEMBL20683710 0.92 CASP2 (0.74) CASP2NAAADNM1FAAHEPHX1
SCHEMBL13317011 0.89 CASP2 (0.59) CASP2NAAADNM1FAAHCNR1
SCHEMBL13045401 0.88 CASP2 (0.69) CASP2NAAADNM1FAAHEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731739-A1 NEW COMPOUNDS Givaudan SA (CH) 2026-04-29 EP disclosed
WO-2024261201-A1 NEW COMPOUNDS GIVAUDAN SA (CH) 2024-12-26 WO disclosed
US-20160228572-A9 Immobilised Biological Entities CARMEDA AB (SE) 2016-08-11 US disclosed
US-20130273122-A1 Immobilised Biological Entities CARMEDA AB (SE) 2013-10-17 US disclosed
EP-1503994-A1 SUBSTITUTED (THIOXO)CARBONYLAMINO PHENYL URACILES Bayer CropScience AG (DE) 2005-02-09 EP disclosed
WO-2003093244-A1 SUBSTITUTED (THIOXO)CARBONYLAMINO PHENYL URACILES BAYER CROPSCIENCE AG (DE) 2003-11-13 WO disclosed
US-4735997-A POLYVINYL CHLORIDE OR CHLORINATED POLYETHYLENE YEDA RESEARCH & DEVELOPMENT COMPANY LIMITED (IL) 1988-04-05 US disclosed
US-4654391-A MODIFIED CHLORINE CONTAINING POLYMER SUBSTITUTED BY THIO AMINE GROUPS, FILMS YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IT) 1987-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130273122-A1 Immobilised Biological Entities FGB, SELE, EPCAM CASP2 2014/4885NAAA 1513/4885DNM1 4602/4885
US-20160228572-A9 Immobilised Biological Entities FGB, SELE, EPCAM CASP2 2014/4885NAAA 1513/4885DNM1 4602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.